Sirolimus
Near Add Your Location
Accepting patients
Donor Lymphocyte Infusion Post Transplant
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
- Donor Lymphocyte Infusion (DLI)
- Post-Allogeneic Stem Cell Transplant
- Phase 1/2
Accepting patients
Graft Versus Host Disease-Reduction Strategies
A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)
- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- Allogeneic Stem Cell Transplant
- Monoclonal Antibody
- CD38
- Phase 1
Accepting patients
Post-Transplant Cytoxan
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
- Xanthine Oxidase Inhibitor
- Phase 2
Showing 1-4 of 4